Investor News

05.06.2023

Successful financial year 2022 for Exentis

• 14 Exentis 3D systems sold – triple compared to 2021
• Solid operating performance in financial year 2022 – run rate CHF 26.0 million
• Positive EBITDA before extraordinary one-off effects

10.05.2023

Exentis appoints Eric Bert as President Exentis Americas

• Exentis accelerates internationalization by expanding into the USA
• Establishment of sales and service network via newly formed entity Exentis North America, Inc.
• Exentis attracted Eric Bert, an experienced executive

03.05.2023

Successful trade fair presence of Exentis

• Participation in German Hannover Messe trade fair exceeds all expectations
• High interest in Exentis 3D technology platform
• Strategic business area New Energy in the focus

24.03.2023

Exentis’ licensee Laxxon Medical enters into a cooperation with Hovione for the industrial manufacturing of 3D printed tablets

• Conclusion of a long-term strategic cooperation agreement between Laxxon Medical and Hovione, a leading manufacturer in the pharmaceutical industry
• Accelerated establishment of the Exentis clean room 3D technology platform within the pharmaceutical industry
• Large-scale production of innovative 3D printed tablets with a freely adjustable release profile for the active pharmaceutical ingredients

22.02.2023

Third 3D production system delivered to Ohnhäuser

• Contract manufacturing capacity for Exentis customers significantly increased to 10 million parts
• Production and development cooperation with Ohnhäuser further extended
• Exentis 3D production system delivered within six weeks

17.01.2023

Ohnhäuser acquires third Exentis 3D production system

• Ohnhäuser being the exclusive contract manufacturer for Exentis since 2019
• Significant expansion of contract manufacturing capacity for Exentis customers
• Series production capacity increased to more than 10 million parts per year

20.12.2022

PHENOGY acquires first Exentis 3D system

• PHENOGY acquires first Exentis 3D system in addition to exclusive production license
• Exentis 3D technology platform to be used for large-scale production of sustainable energy storage systems
• Delivery of the 3D system to PHENOGY still in 2022

16.12.2022

Successful start up of the first Exentis 3D system in Japan

• Delivery and start-up of the first Exentis 3D system in Japan successfully completed
• Exentis showroom at Sintokogio opened
• Already several projects with Japanese customers initiated by Sintokogio

08.12.2022

3D community member Whitecell Power receives 3D production system

• Exentis delivers another 3D system
• Intended use is final development of innovative bipolar plates for fuel cells
• Whitecell Power secures option to purchase a second 3D system

24.11.2022

New Exentis website for further growth and internationalization of the Group

• Target group-oriented communication for further internationalization of the Group
• Early information and enthusiasm for Exentis’ Industrialized Additive Manufacturing
• First element of comprehensive realignment of the marketing strategy

28.09.2022

Exentis’ 3D Community member Whitecell Power presents first own fuel cell powered van

• Exclusive Whitecell Power customer event at the Exentis 3D Innovation Center
• Whitecell Power presents first own fuel cell powered van “Whitecell Power e-Crafter”
• Exentis manufactures next generation of bipolar plates for Whitecell Power’s fuel cells

15.09.2022

High attention for Exentis’ 3D technology in Japan

• Exentis on the front page of the Nikkan Kogyo Shimbun
• Great interest in Exentis’ Industrialized Additive Manufacturing
• Positive momentum for further expansion of the Exentis 3D Community in Japan expected

30.08.2022

Most successful first half year in corporate history

• Turnover revenue of CHF 10 million generated
• 7 systems already sold in the first half, compared to 5 systems in the entire financial year 2021
• Additional “contracted business” (in CHF million) in the mid single digit range

06.07.2022

Major order for production of pharmaceutical cleanroom 3D systems

• Laxxon Medical orders three Exentis 3D production systems
• Expansion of 3D tablet production in the USA and Europe
• Delivery to begin in current year

30.06.2022

Exentis Group AG – Annual General Meeting 2022

• Shareholders approve all proposals of the Board of Directors
• Discharge of the Board of Directors
• Creation of new authorized capital

24.06.2022

Expansion of internationalisation strategy – Conclusion of distribution partnership in Japan

• With Sintokogio Ltd., Exentis gains experienced technology distributor in Japan
• Opening of Japanese showroom in preparation
• First Exentis 3D system placed in Japan

25.05.2022

Successful Rapid.Tech 3D trade fair for Exentis

• High interest in Exentis technology platform
• Particular demand in the core segment “New Energy”
• Sustainability aspects of the technology increasingly important

18.05.2022

2021 most successful business year of Exentis

• Sales CHF 20 million, EBITDA CHF 3.5 million
• First Exentis 3D system placed in the USA
• Presentation of annual report on June 08, 2022

15.03.2022

Value chain completed

• Core functions expanded with more than 50 new employees
• Engineering, steering IT as well as final assembly significantly strengthened
• Accelerated realisation of 3D systems

09.03.2022

Capital increase successfully completed

• Capital increase of CHF 15 million successfully completed
• Potential for growth investments created
• Fiscal year 2021 the most successful in the company’s history

01.12.2021

Successful trade fair presence of Exentis Group

• Strong response to trade fair presence at productronica in Munich
• Various application possibilities in the field of electronics

04.11.2021

Exentis Group and Fraunhofer IFAM amplify co-operation

• Fraunhofer IFAM Dresden launches new Exentis 3D development system for 3D screen printing
• Connecting application development and industrialized 3D production

24.09.2021

Exentis Group successfully represented at two trade fairs

• In Lucerne at the Additive Manufacturing Expo (AM Expo)
• In Munich at the ceramitec conference
• Great demand for the Exentis 3D technology platform, the only Industrialized Additive Manufacturing

04.08.2021

Profitable growth in the first half of 2021

• Shipping of numerous Exentis 3D systems and concluding further licensing agreements
• Revenue of CHF 9.55 million and earnings before interest and taxes (EBIT) of CHF 2.39 million generated
• Full-year outlook: Continued double-digit profitable growth

25.06.2021

Exentis Group AG – Annual General Meeting 2021

• Shareholders approve all proposals of the Board of Directors
• Discharge and re-election of the Board of Directors
• Election of BDO as auditors for the financial year 2021

02.06.2021

Exentis Group AG – Profitable growth

• Obtaining of new development projects, licenses, and orders
• Revenue of the first five months of 2021 higher than total revenue of the most successful year to date

01.06.2021

Exentis Group AG – Successful internationalisation

• Delivery of the first three out of four Exentis 3D systems to Australia
• Production of pharmaceutical products and industrial applications
• Expansion embedded in licensing agreements

27.04.2021

Exentis Group AG – Successful ISO 9001 certification

• Exentis successfully ISO 9001 certified
• Underlines commitment to meet international standards
• Standardised processes support further growth

15.02.2021

Exentis Group AG – Recent developments 2021

• Beginning of 2021 with high demand for Exentis 3D production systems and large-scale production
• Financial year 2020 affected by Corona influences
• From today’s perspective, 2021 will be the most successful financial year ever in the company’s history

10.02.2021

Exentis strengthens management with the appointment of Gereon Heinemann as CEO/COO

• Extensive international board experience in building and leading technology companies
• Many years of market experience in establishing successful 3D business models
• Joint responsibility for the Chief Executive Officer and Chief Operating Officer departments